Adjuvant Treatment of Node-Positive Breast Cancer with Cyclophosphamide, Doxorubicin, Fluorouracil, and Vincristine Versus Cyclophosphamide, Methotrexate, and Fluorouracil: Final Report after a 16-Year Median Follow-Up Duration

Journal of Clinical Oncology

Volumn 14, Issue 4, 1996, Pages 1136-1145

  Misset, Jean Louis ^a   Palma, Mario Di ^b   Delgado, Marian ^b   Plagne, Robert ^b   Chollet, Philippe ^b   Fumoleau, Pierre ^b   Mevel, Bernard Le ^b   Belpomme, Dominique ^b   Guerrin, Jacques ^b   Fargeot, Pierre ^b   Metz, Rolland ^b   Ithzaki, Moshé ^b   Hill, Catherine ^b   Mathé, Georges ^b  

^a HÔPITAL PAUL BROUSSE   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; BCG VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE; MITOMYCIN; NAVELBINE; THIOTEPA; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MENOPAUSE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; SECOND CANCER; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; FRANCE; HUMANS; LYMPHATIC METASTASIS; METHOTREXATE; MIDDLE AGED; NEOPLASM STAGING; POSTMENOPAUSE; PREMENOPAUSE; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0029926323     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.4.1136     Document Type: Article

References (33)

1. Bonadonna G, Brusamolino E, Valagussa P: Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294:405-410, 1976
2. Gouveia J, Misset JL, Bayssas M, et al: Immunotherapy by BCG interspersed with combination chemotherapy in advanced breast carcinoma. Med Oncol 4:13, 1978 (abstr 49)
3. Plagne R, Misset JL, Belpomme D, et al: BCG adjuvant immunotherapy after adjuvant chemotherapy for operable breast cancer. A "Group Inter-France" randomized trial. Proc Am Assoc Cancer Res 23:157, 1982 (abstr 617)
4. Gutterman JU, Cardenas JO, Blumenschein GR, et al: Chemoimmunotherapy of advanced breast cancer: Prolongation of remission and survival with BCG. Br Med J 2:1222-1225, 1976
5. Misset JL, De Vassal F, Jasmin C, et al: Five-year results of the French adjuvant trial for breast cancer comparing CMF to a combination of Adriamycin (ADM), vincristine (VCR), cyclophosphamide (CPM), and 5-fluorouracil (5FU), in Jones SE, Salmon SE (eds): Adjuvant Therapy of Cancer IV. Philadelphia, PA, Grune & Stratton, 1984, pp 243-251
6. Mathé G, Plagne R, Morice V, et al: Consistencies and variations of observations during serial analyses of a trial of adjuvant chemotherapy in breast cancer, in Salmon SE (ed): Adjuvant Therapy of Cancer V. Philadelphia, PA, Grune & Stratton, 1987, pp 271-280
7. Misset JL, Gil-Delgado M, Chollet P, et al: Ten years results of the French trial comparing Adriamycin, vincristin, 5-fluorouracil and cyclophosphamide to standard CMF as adjuvant therapy for node positive breast cancer. Proc Am Soc Clin Oncol 11:54, 1992 (abstr 41)
8. Bonadonna G, Valagussa P, Moliterni A, et al: Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. The results of 20 years of follow-up. N Engl J Med 332:901-906, 1995
9. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results. JAMA 273:542-547, 1995
10. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
11. Bonadonna G, Valagussa P: Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15, 1981
12. Fischer B, Carbone P, Econompou SG, et al: Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 292:117-122, 1975
13. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339:1-15, 71-85, 1992
14. Aisner J, Weinberg V, Perloff M, et al: Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF ± MER) for metastatic carcinoma of the breast: A CALGB study. J Clin Oncol 5:1523-1533, 1987
15. Cummings FJ, Gelman R, Horton J: Comparison of CAF versus CMFP in metastatic breast cancer: Analysis of prognostic factors. J Clin Oncol 3:932-940, 1985
16. Valagussa P, Tancini G, Bonadonna G: Second malignancies after CMF for resectable breast cancer. J Clin Oncol 5:1138-1142, 1987
17. Nissen Meyer R, Kjellgren K, Malmio K, et al: Surgical adjuvant chemotherapy. Results with one short course with cyclophosphamide after mastectomy for breast cancer. Cancer 41:2088-2098, 1978
18. Tannock LF, Boyd NF, DeBoer G, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
19. Wood WC, Budman DR, Korzun AH, et al: Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 330:1253-1259, 1994
20. Carpenter UT, Velez-Garcia E, Aron BS, et al: Five-year results of a randomized comparison of cyclophosphamide, doxorubicin (Adriamycin) and fluorouracil (CAF) vs cyclophosphamide. methotrexate and fluorouracil (CMF) for node positive breast cancer. A Southeastern Cancer Study Group Study. Proc Am Soc Clin Oncol 13:66, 1994 (abstr 68)
21. A'Hern RP, Smith IE, Ebbs SR: Chemotherapy and survival in advanced breast cancer: The inclusion of doxorubicin in Cooper type regimens. Br J Cancer 67:801-805, 1993
22. Buzzoni R, Bonadonna G, Valagussa P, et al: Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and fluorouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 9:2134-2140, 1991
23. Fisher B, Redmond C, Wickerman DL, et al: Doxorubicin-containing regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience. J Clin Oncol 7:572-582, 1989
24. Beuzeboc P, Mosseri V, Dorval T, et al: Adriamycin-based combination chemotherapy significantly improves overall survival in high risk premenopausal breast cancer patients. Proceedings of the 14th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 6-7, 1991 (abstr 40)
25. Semiglazov VF, Golubeva OM: Adriblastin vs. CMF in adjuvant treatment of breast cancer (T3 N0-2 M0). Anticancer Drugs 6:77, 1995 (suppl 2; abstr)
26. Moliterni A, Bonadonna G, Valagussa P: Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive axillary nodes. J Clin Oncol 9:1124-1130, 1991
27. Fisher B, Wickerham DL, Redmond C, et al: Increased benefit from addition of Adriamycin to adjuvant therapy for stage II breast cancer: Results from NSABP protocols B-II and B-12. Proc Am Soc Clin Oncol 6:62, 1987 (abstr 243)
28. Fisher B, Brown AM, Dimitrov NV, et al: Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotexate, and fluorouracil in positive-node breast cancer patients with tamoxiten-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 8:1483-1496, 1990
29. Marty M, Bliss JM, Coombes RC, et al: Cyclophosphamide (C), methotrexate (M), fluorouracil (F) (CMF) versus F-epirubicin (E)-C chemotherapy in premenopausal women with node positive breast cancer: Results of a randomized trial. Proc Am Soc Clin Oncol 13:62, 1994 (abstr 50)
30. Coombes RC, Bliss JM, Wils J, et al: Adjuvant cyclophosphamide, methotrexate. 5-fluorouracil (CMF) versus 5-fluorouracil, epirubicin, cyclophosphamide (FEC) chemotherapy in premenopausal women with node positive operable breast cancer: Results of a randomized trial. J Clin Oncol 14:35-45, 1996
31. Mauriac L, Durand M, Chauvergne J, et al: Randomized trial of adjuvant chemotherapy for operable breast cancer comparing IV CMF to an epirubicin-containing regimen. Ann Oncol 3:439-443, 1992
32. Peters WP, Petros WP, Gupton C, et al: The effect of induction chemotherapy dose intensity on complete response frequency in early metastatic breast cancer. Proc Am Soc Clin Oncol 13:87, 1994 (abstr 150)
33. Goldhirsch A, Gelber RD, Price KN, et al: Effect of systemic adjuvant treatment on first sites of breast cancer relapse. Lancet 343:377-381, 1994